Driven in part by retroactive fees imposed upon pharmacies by pharmacy benefit managers (“PBMs”) and compounded by recent high profile cases of significant price increases for relatively common drugs,1 both retail and institutional pharmacies have continued to push for enhanced prescription drug pricing transparency. Recent state and federal legislation, as well as lawsuits filed by coalitions... READ MORE
Efforts to Enhance Prescription Drug Pricing Transparency Gaining Traction: Implications for Pharmacy Stakeholders
Posted on November 30, 2016 in Health Law News
Published by: Hall Render
